Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 30, 2010

EU Approves Roche’s Xeloda Combined with Oxaliplatin for Post-Surgical Colon Cancer Therapy

  • Roche confirmed European approval of Xeloda (capecitabine) as combination therapy with oxaliplatin for the post-surgical treatment of patients with early colon cancer. Approval is based on results from the pivotal NO16968 trial. Label extensions covering the Xeloada-oxaliplatin combination (commonly known as XELOX), are also expected in other territories Roche stated. Xeloda monotherapy is already approved in Europe, the U.S. and Japan and elsewhere, for the immediate post-surgical treatment of colon cancer patients.

    First licensed in 2001, Xeloda is now available in over 100 countries as either monotherapy or combination therapy for the treatment of colorectal cancer, gastric cancer, and metastatic breast cancer.

    The drug made sales of CHF1.26 billion ($1.18 billion) in 2009, up 7% on sales in 2008.

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »